Calidi Biotherapeutics, Inc.
CLDI- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001855485
No open-market purchases or sales by Calidi Biotherapeutics, Inc. insiders were filed in the last 90 days; 23 institutions reported holding it in 13F filings for Q2 2026, worth $89.3K in total; no superinvestor holds it.
Other share classesCLDWW
Q2 2026 vs. Q1 2026
How the institutions holding Calidi Biotherapeutics, Inc. changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Q2 2026 | Change |
|---|---|---|---|
| Holders | 28 | 23 | −5 |
| Shares | 2.01M | 525.5K | −1.48M (−73.8%) |
| Value | $478.8K | $89.3K | −$389.4K (−81.3%) |
New holders (4)
Institutions that held Calidi Biotherapeutics, Inc. at the end of Q2 2026 but not at the end of Q1 2026.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Independent Advisor Alliance | 45,000 | $7.65K | 0.00% |
| Private Advisor Group, LLC | 30,000 | $5.10K | 0.00% |
| RFG Advisory, LLC | 12,000 | $2.04K | 0.00% |
| UBS Group AG | 7,882 | $1.34K | 0.00% |
Sold out (9)
Institutions that held Calidi Biotherapeutics, Inc. at the end of Q1 2026 and filed for Q2 2026 without it.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| Armistice Capital, LLC | 879,000 | $209.9K |
| Sabby Management, LLC | 434,903 | $103.9K |
| Warberg Asset Management LLC | 250,000 | $59.5K |
| Virtu Financial LLC | 75,769 | $18.0K |
| Vanguard Fiduciary Trust Co | 9,219 | $2.20K |
| HRT Financial LP | 10,133 | $2.00K |
| Apollo Management Holdings, L.P. | 1,042 | $249 |
| FMR LLC | 255 | $61 |
| CVA Family Office, LLC | 42 | $10 |